iBio financials
$1.170.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 | FY18 Jun 30 | FY17 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.0K | $400.0K | $225.0K | $0.00 | $1.9M | $2.4M | $1.6M | $2.0M | $444.0K | $394.0K |
| Gross profit | $100.0K | $400.0K | $225.0K | $0.00 | $1.9M | $909.0K | $935.0K | $2.0M | $444.0K | $394.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 38.3% | 57.1% | 100.0% | 100.0% | 100.0% |
| Operating income | -$35.1M | -$18.6M | -$16.6M | -$29.3M | -$29.7M | -$20.9M | -$14.0M | -$15.8M | -$14.2M | -$14.3M |
| Net income | -$33.0M | -$18.4M | -$24.9M | -$65.0M | -$50.4M | -$23.5M | -$38.3M | -$17.9M | -$16.4M | -$14.6M |
| Net margin | −33044.0% | −4594.3% | −11069.8% | — | −2674.7% | −989.8% | −2335.8% | −884.7% | −3685.8% | −3711.2% |
| Diluted EPS | $-0.32 | $-1.75 | $-6.50 | $-106.19 | $-115.60 | $-60.00 | $-305.00 | $-470.00 | $-770.00 | $-820.00 |
| EBITDA | -$29.6M | -$18.1M | -$15.9M | -$28.3M | -$25.9M | -$30.3M | -$13.4M | -$14.0M | -$12.5M | -$12.6M |
| Operating cash flow | -$23.2M | -$15.3M | -$18.6M | -$30.4M | -$37.5M | -$30.1M | -$13.3M | -$14.0M | -$13.5M | -$13.2M |
| Free cash flow | -$23.8M | -$15.3M | -$18.8M | -$36.2M | -$44.8M | -$35.0M | -$14.4M | -$14.9M | -$14.4M | -$14.5M |
| Diluted shares | 104.1M | 10.5M | 3.8M | 0.6M | 0.4M | 0.4M | 0.1M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $56.4M | $8.6M | $14.2M | $4.3M | $22.7M | $77.4M |
| Short-term investments | $31.6M | $0.00 | $0.00 | $0.00 | $10.8M | $19.6M |
| Total debt | $0.00 | $883.0K | $1.7M | $14.0M | $22.2M | $32.7M |
| Total assets | $99.1M | $23.2M | $28.7M | $41.2M | $99.4M | $147.0M |
| Total liabilities | $13.4M | $8.3M | $7.4M | $25.8M | $35.9M | $38.4M |
| Shareholders' equity | $85.7M | $14.9M | $21.3M | $15.4M | $63.5M | $108.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology